Oncology Drugs

A new subcutaneous autoinjector for Alzheimer's drug Leqembi could soon transform care for millions in China, moving treatment from hospital to home.

Australian biotech Immutep reaches a key milestone in its Phase III trial for a novel lung cancer therapy, a major step in a multi-billion dollar market.

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

A new cancer drug using DNA fragments to deliver chemotherapy more safely has been cleared for US trials, offering hope for less toxic treatments.

Ascentage Pharma's next-gen BTK degrader, APG-3288, receives dual IND clearance, paving the way for clinical trials to fight resistant blood cancers.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

Corcept Therapeutics' stock plummeted and it now faces legal probes after the FDA rejected its key drug, revealing the company was warned not to apply.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.

A $10M investment from pharma giant Dr. Reddy’s validates Coya Therapeutics' novel ALS drug, funding the path to commercial-scale manufacturing.

A new dual-action tablet shows major promise for prostate cancer patients with BRCA mutations, poised to change the standard of care in Europe.